Skip to content

The effects of Skekar Tighal on covid-19

The effects of Trehala Manna (Shekar Tighal) on inflammatory and biochemistry biomarkers, and clinical outcomes in Covid-19 patients; A randomized double-blind placebo-controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211029052904N1
Enrollment
60
Registered
2021-12-30
Start date
2021-12-06
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Pneumonia due to SARS-associated coronavirus

Interventions

Intervention 1: Intervention group: 2 sachets of Trehala manna (refined Shekar Tighal) daily, 5 grams per sachet (a total of 10 grams per day in the form of a drink solution) for 7 days. In addition t

Sponsors

Artesh University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18-65 Written informed consent Covid-19 patients (PCR positive test or clinical symptoms such as fever > 38, respiratory rate = 24, dry cough, myalgia, asthenia, anosmia, and or anorexia Admission to general corvid-19 unit in hospital Patients who estimate that reside in hospital at least 7 days. Non ICU patients

Exclusion criteria

Exclusion criteria: Did not write informed consent Pregnancy and lactation Smoking Usage of other herbal medicine Hypertension (definition by ACC/AHA SBP/DBP = 130/80)

Design outcomes

Secondary

MeasureTime frame
Hospitalization days. Timepoint: Continuous. Method of measurement: Discharge day minus first day.

Primary

MeasureTime frame
C reactive protein. Timepoint: At baseline (day 0) and end of the study (day 8). Method of measurement: ELISA commercial diagnostic kit.;Assess the severity of cough. Timepoint: At baseline (day 0) and end of the study (day 8). Method of measurement: Visual Analogue Scale.;Alanine transaminase. Timepoint: At baseline (day 0) and end of the study (day 8). Method of measurement: Spectrophotometry.;Aspartate transaminase. Timepoint: At baseline (day 0) and end of the study (day 8). Method of measurement: Spectrophotometry.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi keshani

Artesh University of Medical Sciences

mahdikeshani1@yahoo.com+98 21 4382 2449

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026